The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Can diet impact treatment outcomes and progression of patients with multiple myeloma?
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, shares some insights into how diet may impact the progression of multiple myeloma and its precursors. Dr Lesokhin first notes that questions from patients around how they can support their treatment with dietary changes are often poorly addressed because of the lack of clear, definitive studies. Following this, Dr Lesokhin describes studies which suggest that the consumption of more plant-based dietary products may benefit treatment outcomes, but highlights the need for further investigation into these effects. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Genmab, Sanofi, Iteos, BMS, Janssen: Consultancy; Memorial Sloan Kettering Cancer Center: Current Employment; Janssen, Pfizer, BMS, Genentech/Roche: Research Funding; Janssen, Pfizer, Iteos, Sanofi, Genmab: Honoraria; Serametrix, inc: Patents & Royalties; Trillium Therapeutics: Consultancy, Research Funding; Sanofi: Research Funding; BMS: Honoraria; Amgen: Honoraria.
